Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen - Related Studies

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen (PAPRIKA)

This study is currently recruiting participants.

Study NCT00417209. Last updated on August 29, 2008. Information provided by Sanofi-Aventis

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Pancreatic Neoplasms

2	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Neoplasms
		Neoplasms by Site
		Pancreatic Diseases

3	Interventions listed in this trial
		larotaxel (XRP9881)
		5-Fluorouracil

4	Additional drug interventions recognized in this trial
		Fluorouracil
		Gemcitabine

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		Sanofi-Aventis